x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DMM-001158
| Status | Age | Sex |
|---|---|---|
|
|
|
| Product Overview | |
|---|---|
| Model Description | A CreERT2-pA expression cassette was knocked into the Nkx2-1 gene start codon site. Nkx2-1, a key molecule in lung development, is expressed in adult bronchial and alveolar type II epithelial cells. Besides, Nkx2-1 expression as a prognostic marker is also been applied to lung cancer research including lung adenocarcinoma. |
| Strain Name | C57BL/6J-Nkx2-1em1(CreERT2-pA) |
| Background Strain | C57BL/6J |
| SPF | Yes |
| Research Application | Cre recombinase tool. |
| Target Information | |
|---|---|
| Target Name | Nkx2 |
| Synonyms | T/EBP, Titf1, Ttf-1, Nkx2.1, AV026640 |
| Gene ID | 21869 |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
